Abstract
Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macrophages. Adults with moderately active disease (CDAI > 220-450 plus C reactive protein ≥ 5 mg/l and/or fecal calprotectin > 250 μg/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks. Primary endpoints were remission (CDAI ≤ 150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding (CDAI fall by > 70) by 10 weeks were invited to crossover onto the alternative therapy. Fifty-nine patients were recruited across 8 sites. Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P ...Continue Reading
References
Sep 29, 1994·The New England Journal of Medicine·P RutgeertsH Lorenz-Meyer
Mar 1, 1996·Clinical and Diagnostic Laboratory Immunology·B SendidD Poulain
Dec 31, 1998·Glycoconjugate Journal·M YoungE F Hounsell
Feb 12, 2002·Inflammatory Bowel Diseases·George L ArnoldWilliam J Mook
Aug 10, 2004·Gastroenterology·Arlette Darfeuille-MichaudJean-Frédéric Colombel
Aug 17, 2004·The American Journal of Gastroenterology·Paul RyanFergus Shanahan
Feb 14, 2006·Cellular Microbiology·Marie-Agnès BringerArlette Darfeuille-Michaud
May 16, 2006·Gastroenterology·Annie Standaert-VitseDaniel Poulain
Jan 17, 2007·Cellular Microbiology·Sonia MeconiFrédéric Altare
Oct 9, 2007·Gastroenterology·Chiedzo M MpofuJonathan M Rhodes
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Sreedhar SubramanianBarry J Campbell
Nov 13, 2009·Nature·Koji HaseHiroshi Ohno
Sep 4, 2010·Gut·Carol L RobertsBarry J Campbell
Jan 5, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Dirk RoggenbuckKarsten Conrad
Apr 6, 2011·Gut·Craig MowatUNKNOWN IBD Section of the British Society of Gastroenterology
Oct 4, 2011·Bioorganic & Medicinal Chemistry·Oliver SchwardtBeat Ernst
Dec 14, 2011·Gastroenterology·Cosimo PranteraUNKNOWN Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease)
Aug 16, 2013·The Journal of Antimicrobial Chemotherapy·Jean-Christophe LagierDidier Raoult
Jan 17, 2014·Gut·Claire L O'BrienGwen E Allison
Jun 1, 2014·The Journal of Infection·Florence FenollarDidier Raoult
Aug 30, 2014·Cell·Noah W PalmRichard A Flavell
Nov 26, 2014·Journal of Digestive Diseases·Jie Wen SuHong Jie Zhang
Apr 4, 2015·Inflammatory Bowel Diseases·Paul K FlanaganBarry J Campbell
Feb 24, 2016·The American Journal of Gastroenterology·Ana GutiérrezRubén Francés
May 20, 2016·Gut·Claire L O'BrienPaul Pavli
Jun 1, 2016·Inflammatory Bowel Diseases·Sreedhar SubramanianJonathan M Rhodes
Nov 2, 2016·Gut·Sreedhar SubramanianJonathan M Rhodes
Oct 19, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sonja E van RoedenJan Jelrik Oosterheert
Nov 17, 2017·Gut·Carolina PalmelaJean-Frederic Colombel
Feb 9, 2018·Gut·Arie LevineDan Turner
Jan 19, 2019·Journal of the Canadian Association of Gastroenterology·M Ellen KuenzigCynthia H Seow
Apr 23, 2019·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Parambir S DulaiWilliam J Sandborn
Aug 9, 2019·Journal of Crohn's & Colitis·Åsa V KeitaJohan D Söderholm
Feb 2, 2020·Digestive Diseases and Sciences·Akihiko Oka, R Balfour Sartor